CLAIM AMENDMENTS

1. (currently amended) A method of blocking microbial adherence to a eukaryotic cell surface in a mammal by applying to said surface a pharmacologically acceptable composition consisting essentially of ~~isoleucine~~ an amino acid component selected from the group consisting of at least one of the following; L(+) isoleucine, DL-isoleucine, D(-)-allo-isoleucine, L(+)-allo-isoleucine, and active analogs of isoleucine present in a microbial blocking quantity.
2. (original) The method of claim 1 wherein the microbial blocking quantity is in the range of from about 0.1 ug/cm^2 to about 1gm/cm^2 of eukaryotic cell surface area.
3. (original) The method of claim 2 wherein said quantity is from about 3 ug/cm^2 to about 100 ug/cm^2.
4. (original) The method of claim 2 wherein said quantity is from about 10 ug/cm^2 to about 100 ug/cm^2.
5. (currently amended) The method of claim 1 wherein the mammal is ~~man~~ mankind.
6. (currently amended) The method of claim 1 wherein the epithelial surface is one or more of the oral cavity, pharynx, GI tract, respiratory tract, genitourinary tract, skin, eye, and vaginal/cervical area.
7. (original) The method of claim 1 wherein the composition consists of a pure powder of L(+)-isoleucine and/or DL-isoleucine.
8. (original) The method of claim 1 wherein the composition is in the form of a dry powder, a paste, a solution, a gel, a tablet, a lozenge, or a capsule.
9. (currently amended) The method of claim 1 wherein the composition is directly applied to the said epithelial ~~said~~ surface.

10. (currently amended) The method of claim 1 wherein the composition is in the form of a pharmacologically acceptable aqueous composition containing from about 0.01 ug/ml to about 50 ug/ml of ~~isoleucine~~ said amino acid component.

11. (currently amended) A pharmacologically acceptable composition ~~comprising~~ consisting essentially of :

A) from abut 0.001 to about 99% by weight of ~~a compound consisting essentially of isoleucine;~~ an amino acid component selected from the group consisting of at least one of the following; L(+) isoleucine, DL-isoleucine, D(-) –allo-isoleucine, L(+) –allo-isoleucine, and active analogs of isoleucine;

B) at least one additional pharmacologically active substance selected from the group consisting of a fluoride, xylitol, an antibody, an anti-microbial agent, zinc ions, a decongestant, an anesthetic, an anti-oxidant, a vitamin, a microbial substance, a pre-biotic material, folic acid, echinacea, peppermint oil or extract, menthol, quassia, bistort, ginger, angelica, bayberry, chamomile, fish oil or fractionated fish oil, a fatty acid, fiber, flaxseed, a plant extract, garlic or garlic extract, calcium, stannol esters, lutein, zeaxanthin, cryptoxanthin, isoflavone, an anti-inflammatory compound, an antifungal agent, and a food product; and optionally,

C) pharmacologically acceptable carrier materials and/or excipients.

12. (original) The composition of claim 11 wherein component A) is present in from about 0.002 to about 50% by weight.

13. (original) The composition of claim 11 wherein component A) is present in from about 0.1 to about 25% weight.

14. (original) The composition of claim 11 wherein said composition is in the form of a dental care product.

15. (original) The composition of claim 14 wherein component B) is one or more of a fluoride, xylitol, an antibody, and an anti-microbial agent.

16. (original The composition of claim 14 wherein the composition is in the form of a toothpaste or a gel.

17. (cancelled)

18. (currently amended) A toothpaste or gel comprising a eukaryotic cell surface blocking quantity of ~~isoleucine~~ an amino acid component selected from the group consisting of at least one of the following: L(+) isoleucine, DL-isoleucine, D(-)-allo-isoleucine, L(+)-allo-isoleucine, and active analogs of isoleucine.

19-24. (cancelled)

25. (previously amended) The composition of claim 11 wherein component B) is an antifungal and/or antimicrobial substance.

26-30 (cancelled)

31. (previously amended) The composition of claim 11 wherein the composition is in the form of a wound ointment or cream and component B) is one or more of an anti-microbial substance and an anesthetic.

32. (currently amended) a ~~would~~ wound ointment or cream comprising a eukaryotic cell surface

blocking quantity of a compound consisting essentially of ~~isoleucine~~ an amino acid component selected from the group consisting of at least one of the following: L(+) isoleucine, DL-isoleucine, D(-)-allo-isoleucine, L(+)-allo-isoleucine, and active

analogs of isoleucine.

33. (cancelled)

34. (original) The composition of claim 11 wherein the composition is in the form of a skin ointment or cream.

35-40. (cancelled)

41. (new) The method of claim 1 wherein the epithelial surface is one or more of the oral cavity, GI tract, respiratory tract, genitourinary tract, skin, and eye.

42. (new) The method of claim 1 wherein the amino acid component is present in from about 0.1 to 100% by weight of the composition.

43. (new) The method of claim 1 wherein the method is used to treat an infection caused by microbes.

44. (new) The method of claim 43 wherein the microbes are bacteria.